IDMC Recommends Continuation of ELI-002 7P Trial in PDAC
The independent data monitoring committee confirmed the favorable safety profile of ELI-002 7P for the treatment of PDAC in the phase 1/2 AMPLIFY-7P trial.
Previous Post
Exploring GLP-1 Receptor Agonists for Idiopathic Intracranial Hypertension: Dennis Rivet, MD
Next Post
Gastric Submucosal Tumor in Patient Infected with Dioctophyme renale Roundworm, South Korea, 2024
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago